SGMOQ · Sangamo Therapeutics, Inc · Executive Compensation
$0.11
+0.00 (+0.00%)
At close · Nov 18
Return incl. dividend (before tax)
Play latest call
Q1 2026 earnings call transcript
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our history of significant losses, negative cash flows from operations, negative working capital, limited liquidity resources currently on hand and dependence on our ability to obtain additional financing to fund our operations have resulted in management's assessment that there is substantial doubt about our ability to continue as a going concern for at least the next 12 months from the date the financial statements included in this Quarterly Report are issued.”View the 10-Q filed May 14, 2026
Market Cap
$45.57M
Shares
414.29M
Volume · Nov 18
211.89K
Avg daily vol (3M)
1.65M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Alexander D. Macrae | Chief Executive Officer | $2,457,450 |
| Prathyusha Duraibabu | Chief Financial Officer | $1,186,045 |
| Scott B. Willoughby | Chief Legal Officer & Corporate Secretary | $1,139,794 |
| Nathalie Dubois-Stringfellow | Chief Development Officer | $1,132,369 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Alexander D. Macrae | President and Chief Executive Officer | $2,392,272 |
| D. Mark McClung | Former Executive Vice President, Chief Operating Officer | $1,116,596 |
| Prathyusha Duraibabu | Senior Vice President, Chief Financial Officer | $1,057,465 |
| Nathalie Dubois-Stringfellow | Senior Vice President, Chief Development Officer | $1,027,105 |
| Jason Fontenot | Former Senior Vice President, Chief Scientific Officer | $972,242 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Alexander D. Macrae | President and Chief Executive Officer | $4,806,435 |
| D. Mark McClung | Former Executive Vice President, Chief Operating Officer | $1,674,251 |
| R. Andrew Ramelmeier | Executive Vice President, Technical Operations | $1,499,589 |
| Jason Fontenot | Former Senior Vice President, Chief Scientific Officer | $1,414,648 |
| Prathyusha Duraibabu | Senior Vice President, Chief Financial Officer | $1,293,430 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Alexander D. Macrae | President and Chief Executive Officer | $4,735,817 |
| Robert J. Schott | Senior Vice President, Head of Development | $1,899,465 |
| R. Andrew Ramelmeier | Executive Vice President, Technical Operations | $1,690,594 |
| D. Mark McClung | Former Executive Vice President, Chief Operating Officer | $1,657,289 |
| Prathyusha Duraibabu | Senior Vice President, Chief Financial Officer | $1,056,750 |
| Sung H. Lee | Former Executive Vice President, Chief Financial Officer | $47,956 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Alexander D. Macrae | President and Chief Executive Officer | $3,835,030 |
| D. Mark McClung | Executive Vice President, Chief Operating Officer | $2,671,226 |
| R. Andrew Ramelmeier | Executive Vice President, Technical Operations | $1,534,700 |
| Sung H. Lee | Former Executive Vice President, Chief Financial Officer | $1,442,217 |
| Stéphane Boissel | Former Executive Vice President, Corporate Strategy | $1,433,976 |
| Gary H. Loeb | Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer | $1,393,313 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Alexander D. Macrae | President and Chief Executive Officer | $3,986,555 |
| Sung H. Lee | Former Executive Vice President, Chief Financial Officer | $2,530,680 |
| Adrian Woolfson | Executive Vice President, Research and Development | $2,310,510 |
| Gary H. Loeb | Executive Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer | $2,043,025 |
| Stéphane Boissel | Former Executive Vice President, Corporate Strategy | $1,485,282 |
| R. Andrew Ramelmeier | Executive Vice President, Technical Operations | $1,104,540 |
| Kathy Y. Yi | Former Executive Vice President and Chief Financial Officer | $1,069,587 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Alexander D. Macrae | President and Chief Executive Officer | $4,104,428 |
| Stéphane Boissel | Former Executive Vice President, Corporate Strategy | $2,590,066 |
| Kathy Y. Yi | Former Executive Vice President and Chief Financial Officer | $1,266,580 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Alexander D. Macrae | President and Chief Executive Officer | $1,795,856 |
| Kathy Y. Yi | Former Executive Vice President and Chief Financial Officer | $994,005 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Nikunj Jain | Interim Chief Financial Officer | Appointed | 2026-02-03 |
| Prathyusha Duraibabu | principal financial officer | Terminated | 2026-02-03 |
| Nikunj Jain | principal accounting officer | Appointed | 2025-09-30 |
| Prathyusha Duraibabu | Chief Financial Officer | Resigned | 2025-09-30 |
|
Prathyusha Duraibabu
“Ms. Duraibabu’s resignation is not due to any disagreement relating to the Company’s operations, financial statements, internal controls, auditors, policies or practices.”
|
Chief Financial Officer | Resigned | 2025-09-11 |
| James R. Meyers | Director | Appointed | 2025-06-16 |
| H. Stewart Parker | Director | Appointed | 2025-06-16 |
| Karen L. Smith, M.D., Ph.D., M.B.A., L.L.M. | Director |
Already on the board
Since at least 2023: re-election or new board role
|
2025-06-16 |
| John H. Markels, Ph.D. | Director |
Already on the board
Since at least 2023: re-election or new board role
|
2025-06-16 |
| Alexander D. Macrae, M.B., Ch.B., Ph.D. | Director |
Already on the board
Since at least 2023: re-election or new board role
|
2025-06-16 |
| Margaret A. Horn, J.D. | Director |
Already on the board
Since at least 2023: re-election or new board role
|
2025-06-16 |
| Robert F. Carey | Director | Appointed | 2025-06-16 |
| Kenneth J. Hillan, M.B., Ch.B. | Director |
Already on the board
Since at least 2020: re-election or new board role
|
2025-06-16 |
| Courtney Beers, Ph.D. | Director |
Already on the board
Since at least 2023: re-election or new board role
|
2025-06-16 |
| Karen L. Smith, M.D., Ph.D., M.B.A., L.L.M. | Director | Appointed | 2024-06-05 |
| H. Stewart Parker | Director | Appointed | 2024-06-05 |
| James R. Meyers | Director | Appointed | 2024-06-05 |
| John H. Markels, Ph.D. | Director | Appointed | 2024-06-05 |
| Margaret A. Horn, J.D. | Director | Appointed | 2024-06-05 |
| Alexander D. Macrae, M.B., Ch.B., Ph.D. | Director | Appointed | 2024-06-05 |
| Robert F. Carey | Director | Appointed | 2024-06-05 |
| Kenneth J. Hillan, M.B. | Director | Appointed | 2024-06-05 |
| Courtney Beers, PhD. | Director | Appointed | 2024-06-05 |
| Karen L. Smith, M.D., Ph.D., M.B.A., L.L.M. | Director | Appointed | 2023-06-02 |
| H. Stewart Parker | Director | Appointed | 2023-06-02 |
Leadership
- Alexander D. Macrae CEO, Board Member
- Kathy Y. Yi CFO
- Nikunj Jain CFO, Chief Accounting Officer
- Sung H. Lee CFO
- D. Mark McClung COO
- Scott B. Willoughby General Counsel
- Alexander D. Macrae, M.B., Ch.B., Ph.D. Board Member
- Courtney Beers Board Member
- Courtney Beers, Ph.D. Board Member
- Courtney Beers, PhD. Board Member
- Dr. John Markels Board Member
- H. Stewart Parker Board Member
- James R. Meyers Board Member
- John H. Markels Board Member
- John H. Markels, Ph.D. Board Member
- Joseph S. Zakrzewski Board Member
- Karen L. Smith Board Member
- Karen L. Smith, M.D., Ph.D., M.B.A., L.L.M. Board Member
- Kenneth J. Hillan Board Member
- Kenneth J. Hillan, M.B. Board Member
- Kenneth J. Hillan, M.B., Ch.B. Board Member
- Margaret A. Horn Board Member
- Margaret A. Horn, J.D. Board Member
- Robert F. Carey Board Member
- Saira Ramasastry Board Member
- Stephen G. Dilly, M.B.B.S, Ph.D. Board Member
Key facts
CIK
1001233
CUSIP
800677106
13F (30d)
21 filings
4 filers
Visit website
Investor relations